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Introduction {#ehf212057-sec-0004}
============

Chronic heart failure (CHF) is an increasing socioeconomic burden on health‐care systems, and hospitalizations due to heart failure make a significant contribution to the overall cost.[1](#ehf212057-bib-0001){ref-type="ref"}, [2](#ehf212057-bib-0002){ref-type="ref"} Therefore, reliable risk stratification to identify CHF patients at risk of admission for worsening heart failure (WHF) is of great importance. Previous studies demonstrated that right ventricular (RV) systolic dysfunction predicts poor prognosis in CHF patients.[3](#ehf212057-bib-0003){ref-type="ref"}, [4](#ehf212057-bib-0004){ref-type="ref"}, [5](#ehf212057-bib-0005){ref-type="ref"}, [6](#ehf212057-bib-0006){ref-type="ref"} In addition, cardiac iodine‐123 (I‐123) metaiodobenzylguanidine (MIBG) imaging also predicts poor outcome in CHF patients.[7](#ehf212057-bib-0007){ref-type="ref"}, [8](#ehf212057-bib-0008){ref-type="ref"}, [9](#ehf212057-bib-0009){ref-type="ref"}, [10](#ehf212057-bib-0010){ref-type="ref"}, [11](#ehf212057-bib-0011){ref-type="ref"} However, little is known about the predictive value of combining RV systolic dysfunction and MIBG imaging on long‐term outcome in CHF patients.

Aims {#ehf212057-sec-0005}
----

The aim of the current study was to investigate whether cardiac I‐123 MIBG imaging provides additional prognostic information over RV systolic dysfunction in patients with CHF.

Methods {#ehf212057-sec-0006}
=======

Patients {#ehf212057-sec-0007}
--------

Sixty‐three CHF outpatients with radionuclide left ventricular (LV) ejection fraction (EF) \<40% were enrolled in a prospective cohort study. CHF was defined according to Framingham criteria.[12](#ehf212057-bib-0012){ref-type="ref"} Patients were required to be stable for ≥3 months on conventional therapy. Patients with significant renal failure (serum creatinine \>3.0 mg/dL), insulin‐dependent diabetes mellitus, or autonomic neuropathy were excluded. None had had implantable cardioverter defibrillators, biventricular pacemakers, or biventricular defibrillators at enrollment. At entry, radionuclide angiography, cardiac MIBG imaging, and echocardiography were performed; and a venous blood sample was drawn. All patients gave written informed consent. The study complied with the Declaration of Helsinki and was approved by our institutional review committee. The primary endpoint of this study was unplanned hospitalization for WHF. Cardiac death was the other study endpoint.

Radionuclide angiography {#ehf212057-sec-0008}
------------------------

Patients underwent electrocardiogram‐gated blood‐pool scintigraphy with a conventional rotating gamma camera (Prism 2000, Picker, Bedford, OH, USA). Patients were given 740 MBq of technetium‐99m‐labelled human serum albumin (Nihon Medi‐Physics, Nishinomiya, Japan). Reduced RVEF was defined as ≤37%.[6](#ehf212057-bib-0006){ref-type="ref"}

Cardiac MIBG imaging {#ehf212057-sec-0009}
--------------------

Myocardial imaging with I‐123 MIBG (Daiichi Radioisotope Laboratory, Tokyo, Japan) was performed with the same gamma camera as that used for radionuclide angiography. A 111 MBq dose of I‐123 MIBG was injected intravenously at rest after an overnight fast. Initial and delayed image acquisitions were performed in the anterior chest view at 20 and 200 min after isotope injection. The heart‐to‐mediastinum ratio and the cardiac MIBG washout rate (WR) were calculated; an abnormal WR was defined as \>27%.[8](#ehf212057-bib-0008){ref-type="ref"}

Echocardiography {#ehf212057-sec-0010}
----------------

Two‐dimensional echocardiography was performed to measure LV end‐diastolic and end‐systolic dimensions and left atrial dimension, and the severity of mitral regurgitation (MR) was graded as previously described.[8](#ehf212057-bib-0008){ref-type="ref"}, [13](#ehf212057-bib-0013){ref-type="ref"}

Statistics {#ehf212057-sec-0011}
----------

Data are presented as the mean ± SD. A Student\'s *t*‐test and Fisher\'s exact test were used to compare differences in continuous and discrete variables, respectively. The prognostic value of baseline characteristics was assessed with a Cox proportional hazards regression analysis. Event‐free survival rates were calculated using the Kaplan--Meier method, and the differences in survival rates were compared between groups with the log‐rank test. A *P* value \<0.05 was considered significant.

Results {#ehf212057-sec-0012}
=======

Comparison of baseline characteristics {#ehf212057-sec-0013}
--------------------------------------

During a follow‐up period of 8.9 ± 4.3 years, 19 of 63 patients had unplanned hospitalization for WHF, and 19 of 63 patients had cardiac death. Although atrial fibrillation was more often observed in patients with cardiac event (unplanned hospitalization for WHF and/or cardiac death), there was no significant difference in the other baseline clinical characteristics between the patients with and without cardiac event (*Table* [1](#ehf212057-tbl-0001){ref-type="table-wrap"}). Patients with cardiac event had significantly larger left atrial dimensions, significantly higher MR grade, significantly lower serum sodium levels, significantly higher serum uric acid levels, and significantly higher plasma noradrenaline levels. Radionuclide RVEF was significantly lower, and WR was significantly higher in patients with than without cardiac event (*Table* [2](#ehf212057-tbl-0002){ref-type="table-wrap"}).

###### 

Baseline clinical characteristics in the study patients with and without cardiac event (unplanned hospitalization for worsening heart failure and/or cardiac death)

  ----------------------------------------------------------------------------------------------------------------
                                                         Withcardiac event\   Without cardiac event\   *P*‐value
                                                         (*n* = 28)           (*n* = 35)               
  ------------------------------------------------------ -------------------- ------------------------ -----------
  Follow‐up time, years                                  7.3 ± 4.3            10.2 ± 3.9               0.0082

  Age, years                                             63 ± 14              62 ± 13                  0.6264

  Male sex, %                                            86                   63                       0.0506

  Ischemic origin, %                                     39                   63                       0.0790

  Diabetes mellitus, %                                   18                   34                       0.1660

  Atrial fibrillation, %                                 39                   9                        0.0054

  Body mass index, kg/m^2^                               22.7 ± 3.6           23.6 ± 3.0               0.2891

  Medication                                                                                           

  Diuretics                                                                                            

  Loop, %                                                89                   71                       0.1190

  Spironolactone, %                                      71                   63                       0.5931

  Digitalis, %                                           64                   54                       0.5963

  ACE inhibitor/ARB, %                                   86                   89                       0.9999

  β‐Blocker[a](#ehf212057-note-0003){ref-type="fn"}, %   79                   89                       0.3180

  NYHA functional class                                  2.2 ± 0.7            2.1 ± 0.4                0.3728

  Heart rate, beats/min                                  75 ± 14              74 ± 10                  0.7840

  Systolic blood pressure, mmHg                          125 ± 20             130 ± 19                 0.3037
  ----------------------------------------------------------------------------------------------------------------

ACE, angiotensin‐converting enzyme; ARB, angiotensin II type 1 receptor blocker; NYHA, New York Heart Association; WHF, worsening heart failure.

Data are presented as the mean value ± SD or percentage of patients

Use of β‐blocker (carvedilol), as scored at the last follow‐up visit.

###### 

Baseline characteristics in the study patients with and without cardiac event (unplanned hospitalization for worsening heart failure and/or cardiac death)

  ------------------------------------------------------------------------------------
                             Withcardiac event\   Without cardiac event\   *P*‐value
                             (*n* = 28)           (*n* = 35)               
  -------------------------- -------------------- ------------------------ -----------
  Radionuclide angiography                                                 

  LVEF, %                    28.0 ± 7.6           31.6 ± 6.8               0.0582

  RVEF, %                    43.4 ± 11.9          49.6 ± 10.2              0.0307

  Echocardiography                                                         

  LVEDD, mm                  65.7 ± 7.8           62.1 ± 7.1               0.0588

  LVESD, mm                  54.5 ± 7.7           51.3 ± 8.2               0.1261

  LAD, mm                    47.5 ± 8.8           40.6 ± 5.5               0.0004

  MR grade                   1.3 ± 0.7            0.9 ± 0.6                0.0153

  Sodium, mEq/L              138 ± 3              140 ± 3                  0.0239

  Creatinine, mg/dL          1.00 ± 0.29          0.86 ± 0.26              0.0552

  eGFR, mL/min/1.73m^2^      58.7 ± 16.2          65.5 ± 20.3              0.1516

  Uric acid, mg/dL           7.6 ± 2.1            6.3 ± 1.5                0.0043

  Noradrenaline, pg/mL       535 ± 254            400 ± 250                0.0403

  Cardiac MIBG imaging                                                     

  H/M(e)                     1.78 ± 0.29          1.82 ± 0.25              0.5066

  H/M(d)                     1.59 ± 0.27          1.74 ± 0.32              0.0501

  WR, %                      39.3 ± 13.5          25.0 ± 11.2              \<0.0001
  ------------------------------------------------------------------------------------

eGFR, estimated glomerular filtration rate; H/M(d), heart‐to‐mediastinum metaiodobenzylguanidine uptake ratio on the delayed images; H/M(e), heart‐to‐mediastinum metaiodobenzylguanidine uptake ratio on the early images; LAD, left atrial dimension; LVEDD, left ventricular end‐diastolic dimension; LVESD, left ventricular end‐systolic dimension; LVEF, left ventricular ejection fraction; MIBG, metaiodobenzylguanidine; MR, mitral regurgitation; RVEF, right ventricular ejection fraction; WHF, worsening heart failure; WR, washout rate of cardiac metaiodobenzylguanidine.

Data are presented as the mean value ± SD.

Prognostic analysis {#ehf212057-sec-0014}
-------------------

Univariate and multivariate Cox proportional hazard analyses for unplanned hospitalization for WHF and cardiac death are shown in *Table* [3](#ehf212057-tbl-0003){ref-type="table-wrap"}. In multivariate analysis, WR was the independent predictor of both endpoints. In addition, RVEF and New York Heart Association (NYHA) functional class predicted unplanned hospitalization for WHF, and LVEF and the presence of atrial fibrillation predicted cardiac death.

###### 

Univariate and multivariate Cox proportional hazard analyses for the identification of patients at risk for unplanned hospitalization for worsening heart failure and cardiac death

                                                                                            Univariate analysis   Multivariate analysis            
  ----------------------------------------------------------------------------------------- --------------------- ----------------------- -------- ----------------------
  Cox proportional hazard model for unplanned hospitalization for worsening heart failure                                                          
  WR                                                                                        0.0002                1.059 (1.028--1.092)    0.0110   1.039 (1.009--1.070)
  LAD                                                                                       0.0015                1.089 (1.034--1.148)    ---      ---
  RVEF                                                                                      0.0037                0.930 (0.886--0.976)    0.0204   0.929 (0.873--0.988)
  Sodium                                                                                    0.0178                0.838 (0.725--0.969)    ---      ---
  NYHA functional class (III/IV)                                                            0.0228                2.900 (1.165--7.214)    0.0495   2.739 (1.007--7.448)
  MR grade (≧grade 2)                                                                       0.0242                3.102 (1.165--8.257)    ---      ---
  Uric acid                                                                                 0.0301                1.248 (1.023--1.522)    ---      ---
  Atrial fibrillation                                                                       0.0423                2.675 (1.040--6.884)    ---      ---
  Cox proportional hazard model for cardiac death                                                                                                  
  WR                                                                                        0.0004                1.057 (1.025--1.089)    0.0118   1.047 (1.010--1.085)
  Atrial fibrillation                                                                       0.0015                4.349 (1.766--10.708)   0.0293   2.999 (1.123--8.008)
  LAD                                                                                       0.0120                1.066 (1.014--1.120)    ---      ---
  LVEF                                                                                      0.0125                0.927 (0.874--0.984)    0.0091   0.919 (0.862--0.979)
  Creatinine                                                                                0.0273                4.313 (1.186--15.692)   ---      ---
  Uric acid                                                                                 0.0297                1.305 (1.028--1.658)    ---      ---

HR, hazard ratio; CI, confidence interval; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; RVEF, right ventricular ejection fraction; WR, washout rate of cardiac metaiodobenzylguanidine.

Kaplan--Meier analysis showed that patients with an abnormal WR had a significantly higher risk of unplanned hospitalization for WHF regardless of the presence or absence of a reduced RVEF (*Figure* [1](#ehf212057-fig-0001){ref-type="fig"}), although this was not the case for cardiac death (*Figure* [2](#ehf212057-fig-0002){ref-type="fig"}).

![Survival rates from unplanned heart failure hospitalization in patients with and without reduced RVEF. RVEF, right ventricular ejection fraction; CI, confidence interval; HR, hazard ratio; WR, washout rate of cardiac metaiodobenzylguanidine.](EHF2-2-116-g001){#ehf212057-fig-0001}

![Survival rates from cardiac death in patients with and without reduced RVEF. RVEF, right ventricular ejection fraction; CI, confidence interval; HR, hazard ratio; WR, washout rate of cardiac metaiodobenzylguanidine.](EHF2-2-116-g002){#ehf212057-fig-0002}

To better define the risk in individual patients, a predictive model was constructed based on three independent predictors of unplanned hospitalization for WHF identified by multivariate Cox analysis: the presence of abnormal WR, reduced RVEF, and NYHA functional class III/IV. Low‐risk, intermediate‐risk, and high‐risk groups of unplanned hospitalization for WHF (none: 6%, one: 20%, two or three: 80%) or cardiac death (none: 6%, one: 33%, two or three: 53%) were identified according to the number of risk factors (*Figure* [3](#ehf212057-fig-0003){ref-type="fig"}).

![Risk‐stratification model based on abnormal cardiac metaiodobenzylguanidine washout rate, reduced right ventricular ejection fraction, and New York Heart Association functional class III/IV.](EHF2-2-116-g003){#ehf212057-fig-0003}

Discussion {#ehf212057-sec-0015}
==========

Increased sympathetic nerve activity in patients with CHF has been shown to be associated with a poor prognosis,[14](#ehf212057-bib-0014){ref-type="ref"} and cardiac MIBG imaging has been introduced as a useful tool for the estimation of cardiac adrenergic nerve activity.[15](#ehf212057-bib-0015){ref-type="ref"} Since the first report by Merlet *et al.* [7](#ehf212057-bib-0007){ref-type="ref"} that showed the prognostic value of cardiac MIBG imaging in patients with CHF, the predictive value of MIBG imaging has been confirmed in several studies including ours.[8](#ehf212057-bib-0008){ref-type="ref"}, [9](#ehf212057-bib-0009){ref-type="ref"}, [10](#ehf212057-bib-0010){ref-type="ref"}, [11](#ehf212057-bib-0011){ref-type="ref"} The present long‐term, prospective, observational study expands on previous research by demonstrating that cardiac I‐123 MIBG imaging can provide incremental value when it is combined with RV systolic dysfunction to predict clinical outcome in patients with CHF.

Although our result was in line with previous reports showing that RV systolic dysfunction is a predictor of poor prognosis in CHF patients,[3](#ehf212057-bib-0003){ref-type="ref"}, [5](#ehf212057-bib-0005){ref-type="ref"}, [6](#ehf212057-bib-0006){ref-type="ref"} we did not observe a significant association between RV systolic dysfunction and cardiac mortality. This might be explained by the difference in the patients\' background. In our study, patients had mild to moderate symptoms of CHF, and only 15 patients (24%) were in NYHA class III/IV compared with 100% in the study by Meyer *et al*.[5](#ehf212057-bib-0005){ref-type="ref"} Unlike in the study by De Groote *et al.*,[6](#ehf212057-bib-0006){ref-type="ref"} most of the study patients were enrolled before the beta‐blocker era in our study. Moreover, the mean age of our study patients (62 years) was relatively higher than that of previous reports.[3](#ehf212057-bib-0003){ref-type="ref"}, [6](#ehf212057-bib-0006){ref-type="ref"}

Our study was consistent with the report by Manrique *et al.* [4](#ehf212057-bib-0004){ref-type="ref"} in that cardiac sympathetic dysfunction as assessed by cardiac MIBG imaging was an independent predictor of cardiac mortality, while RV systolic dysfunction was not. In addition to the results by Manrique *et al.*, our study demonstrated that cardiac MIBG imaging provided incremental value when it was used along with RV systolic dysfunction to predict poor outcome in CHF patients, showing that a simple risk‐stratification model based on the independent predictors of unplanned WHF hospitalization was useful not only for the prediction of heart failure admission but also for that of cardiac death.

Although RVEF measurement by radionuclide angiography has been considered the gold standard for RV systolic function,[3](#ehf212057-bib-0003){ref-type="ref"}, [4](#ehf212057-bib-0004){ref-type="ref"}, [5](#ehf212057-bib-0005){ref-type="ref"}, [6](#ehf212057-bib-0006){ref-type="ref"} new RV systolic parameters, such as RVEF measured by magnetic resonance imaging or echocardiographic indices, are currently under evaluation.[6](#ehf212057-bib-0006){ref-type="ref"} Further research is needed to identify the best index of RV systolic function and to compare its prognostic value with that of cardiac MIBG imaging in CHF patients.

Limitations of the study {#ehf212057-sec-0016}
========================

There are several limitations to this study. First, this is a single‐centre study, and the number of the study subjects is small. Second, because we included only stable outpatients with mild to moderate heart failure symptoms, one should not generalize our results to patients with severe CHF. Third, we could not include several echocardiographic indices that have been shown to be predictive of clinical outcome of CHF patients[6](#ehf212057-bib-0006){ref-type="ref"}, [16](#ehf212057-bib-0016){ref-type="ref"} in the analysis. Lastly, because most of the study patients were included in our placebo‐controlled study where the efficacy of carvedilol or amlodipine was evaluated last century (T. Yamada *et al.*, unpublished study, 1995 to 1999), no study patient received beta‐blocker therapy at entry. As previously reported, results of cardiac MIBG imaging is influenced by heart failure medications.[17](#ehf212057-bib-0017){ref-type="ref"}, [18](#ehf212057-bib-0018){ref-type="ref"} Therefore, caution should be made when generalizing our results to the recent patients with CHF.

Conclusions {#ehf212057-sec-0017}
===========

We demonstrated that in patients with CHF, cardiac MIBG imaging provided additional prognostic value when it was combined with RV systolic dysfunction. In addition, our result suggested that cardiac MIBG imaging was a more potent predictor of cardiac mortality in CHF patients compared with RV systolic dysfunction. Further studies are needed to compare prognostic value of cardiac MIBG imaging with that of RV systolic parameters and to better risk stratify the patients with CHF.
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